The phase 2/3 DEVOTE trial demonstrated that high-dose nusinersen significantly improved motor function and was safe in patients with spinal muscular atrophy, compared with a matched sham control.
- Richard S. Finkel
- Thomas O. Crawford
- Stephanie Fradette